Palvella Therapeutics
PVLA
49 hedge funds and large institutions have $114M invested in Palvella Therapeutics in 2017 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 5 closing their positions.
480% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 5
126% more capital invested
Capital invested by funds: $50.5M → $114M (+$63.4M)
81% more funds holding
Funds holding: 27 → 49 (+22)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0.09% more ownership
Funds ownership: 0.56% → 0.65% (+0.09%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$5.75M |
| 2 |
BlackRock
New York
|
+$5.1M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.96M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.72M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$4.17M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$4.03M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$1.21M |
| 4 |
Renaissance Technologies
New York
|
-$506K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$139K |
PVLA Hedge Fund Activity: Q2 2017 in Review
49 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2017, worth a combined $114M — up 126% from $50.5M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PVLA positions and 5 closed out — a net gain of 24 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was BVF Inc, adding an estimated $5.75M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $4.17M.
- 49 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2017, up from 27 in Q1 2017.
- Funds reported $114M of Palvella Therapeutics stock for Q2 2017, up 126% quarter-over-quarter.
- 29 funds opened new Palvella Therapeutics positions in Q2 2017 and 5 closed out, a net change of +24 holders.
- The largest Palvella Therapeutics buyer in Q2 2017 was BVF Inc, an estimated $5.75M added.
- The largest Palvella Therapeutics seller in Q2 2017 was Lombard Odier Asset Management (USA), an estimated $4.17M sold.
Based on aggregated 13F filings for Q2 2017.